BMRA: Biomerica, Inc. Stock

by  •  • Comments Off on BMRA: Biomerica, Inc. Stock

SIC 2835 – In Vitro and In Vivo Diagnostic Substances

Valuation
Market Cap ($M) 5.44
Enterprise Value ($M) 2.62
Book Value ($M) 5.35
Book Value / Share 0.32
Price / Book 1.02
NCAV ($M) 3.92
NCAV / Share 0.23
Price / NCAV 1.39

Profitability (mra)
Return on Invested Capital (ROIC) -1.02
Return on Assets (ROA) -0.47
Return on Equity (ROE) -0.57

Liquidity (mrq)
Quick Ratio 2.09
Current Ratio 3.00

Balance Sheet (mrq) ($M)
Current Assets 6.45
Assets 7.87
Liabilities 2.52
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 5.42
Operating Income -6.37
Net Income -5.98
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -5.36
Cash from Investing -0.12
Cash from Financing -0.08

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Granahan Investment Management Inc/ma 3.14 -51.28
02-09 13G Wasatch Advisors Inc

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-10-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2024 or ☐ TRANSITION REPORT PURSUANT
2024-08-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2024 or ☐ Transition Report Pursuant to Section
2024-04-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 29, 2024 or ☐ TRANSITION REPORT PURSUA
2024-01-16 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2023 or ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-22 20,604 130,384 15.80
2024-11-21 25,849 151,591 17.05
2024-11-20 5,693 36,145 15.75
2024-11-19 12,280 56,537 21.72
2024-11-18 15,439 37,806 40.84

(click for more detail)

Similar Companies
BFRI – Biofrontera Inc. BGM – BGM Group Ltd
BIVI – BioVie Inc. BNTC – Benitec Biopharma Inc.
BON – Bon Natural Life Limited


Financial data and stock pages provided by
Fintel.io